Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) for the year ending March 31, 2024: -0.39%

Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) is -0.39% for the year ending March 31, 2024, a -105.09% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 7.70%, a -60.72% change year over year.
Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 19.61%, a -37.62% change year over year.
Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 31.44%, a 141.09% change year over year.
Mangalam Drugs & Organics Limited Return on Capital Employed (ROCE) for the year ending March 31, 2020 was 13.04%, a 432.03% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Chemicals & Advanced Materials Clinical Trials Drugstores & Retail Pharmacies Fertilizers Pharmaceuticals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years